1 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发作的专家共识(更新版)[J]. 中华内科杂志, 2008, 47:873-875.

2 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南2010[J]. 中华神经科杂志, 2010, 43:146-153.

3 Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010:findings from the Global Burden of Disease Study 2010[J]. Lancet, 2013, 381:1987-2015.

4 陈竺. 全国第三次死因回顾性抽样调查报告[M]. 北京:中国协和医科大学出版社, 2008:10-17.

5 Liu M, Wu B, Wang WZ, et al. Stroke in China:epidemiology, prevention, and management strategies[J]. Lancet Neurol, 2007, 6:456-464.

6 The World Bank. Toward a Healthy and Harmonious Life in China:Stemming the Rising Tide of Non-Communicable Diseases[EB/OL]. (2011-07-25)[2013-02-26]. http://www.worldbank.org/content/dam/Worldbank/document/NCD_report_en.pdf.

7 Xu G, Ma M, Liu X, et al. Is there a stroke belt in China and why[J]. Stroke, 2013, 44:1775-1783.

8 Liu L, Wang D, Wong KS, et al. Stroke and stroke care in China:huge burden, significant workload, and a national priority[J]. Stroke, 2011, 42:3651-3654.

9 Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National Stroke Registry (CNSR)[J]. Stroke, 2011, 42:1658-1664.

10 Wang Y, Xu J, Zhao X, et al. Association of hypertension with stroke recurrence depends on ischemic stroke subtype[J]. Stroke, 2013, 44:1232-1237.

11 Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980:systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants[J]. Lancet, 2011, 377:578-586.

12 Yang W, Xiao J, Yang Z, et al. Serum lipids and lipoproteins in Chinese men and women[J]. Circulation, 2012, 125:2212-2221.

13 李立明, 饶克勤, 孔灵芝, 等. 中国居民2002年营养与健康状况调查[J]. 中华流行病学杂志, 2005, 26:478-484.

14 蒋立新, 李希, 李静, 等. 中国动脉粥样硬化性缺血性脑卒中患者他汀类药物应用现状调查[J]. 中华流行病学杂志, 2010, 31:925-928.

15 中华医学会神经病学分会脑血管病学组"卒中一级预防指"撰写组. 中国卒中一级预防指南2010[J]. 中华神经科杂志, 2011, 44:282-288.

16 中国医师协会心血管内科医师分会《中华内科杂志》编辑委员会. 心血管疾病一级预防中国专家共识[J]. 中华内科杂志, 2010, 49:174-185.

17 Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias:The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J]. Atherosclerosis, 2011, 217:3-46.

18 Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. J Am Coll Cardiol, 2004, 44:720-732.

19 Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J]. Stroke, 2004, 35:2902-2909.

20 European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008[J]. Cerebrovasc Dis, 2008, 25:457-507.

21 Naci H, Brugts JJ, Fleurence R, et al. Comparative effects of statins on major cerebrovascular events:a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials[J]. QJM, 2013, 106:299-306.

22 Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with Atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial[J]. Lancet, 2003, 361:1149-1158.

23 Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial[J]. Lancet, 2004, 364:685-696.

24 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005, 352:1425-1435.

25 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359:2195-2207.

26 Everett BM, Glynn RJ, MacFadyen JG, et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein:Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin (JUPITER)[J]. Circulation, 2010, 121:143-150.

27 Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke:the Atherosclerosis Risk in Communities (ARIC) study[J]. Am J Epidemiol, 2000, 151:478-487.

28 Yang EY, Chambless L, Sharrett AR, et al. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study[J]. Stroke, 2012, 43:103-108.

29 Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness:a systematic review and meta-analysis[J]. Circulation, 2007, 115:459-467.

30 Mathiesen EB, Johnsen SH, Wilsgaard T, et al. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke:a 10-year follow-up of 6584 men and women:the Tromsø Study[J]. Stroke, 2011, 42:972-978.

31 Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis[J]. Nature, 2008, 451:904-913.

32 Wasserman BA, Sharrett AR, Lai S, et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI:the multi-ethnic study of atherosclerosis (MESA)[J]. Stroke, 2008, 39:329-335.

33 Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis:the METEOR Trial[J]. JAMA, 2007, 297:1344-1353.

34 Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP):a prospective, randomised, double-blind trial[J]. Lancet, 2001, 357:577-581.

35 Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[J]. JAMA, 2004, 291:1071-1080.

36 Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J]. JAMA, 2006, 295:1556-1565.

37 Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome:demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event:the ESTABLISH Study[J]. Circulation, 2004, 110:1061-1068.

38 Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease[J]. Circulation, 2001, 104:387-392.

39 Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis[J]. Endocr Pract, 2012, 18:1-78.

40 Wong KS, Ng PW, Tang A, et al. Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients[J]. Neurology, 2007, 68:2035-2038.

41 Wong KS, Huang YN, Gao S, et al. Intracranial stenosis in Chinese patients with acute stroke[J]. Neurology, 1998, 50:812-813.

42 Jeng JS, Tang SC, Liu HM, et al. Epidemiology, diagnosis and management of intracranial atherosclerotic disease[J]. Expert Rev Cardiovasc Ther, 2010, 8:1423-1432.

43 Huang HW, Guo MH, Lin RJ, et al. Prevalence and risk factors of middle cerebral artery stenosis in asymptomatic residents in Rongqi Country, Guangdong[J]. Cerebrovasc Dis, 2007, 24:111-115.

44 Bae HJ, Lee J, Park JM, et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics[J]. Cerebrovasc Dis, 2007, 24:355-360.

45 Kim DE, Kim JY, Jeong SW, et al. Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis:a prospective multicenter study[J]. Stroke, 2012, 43:1824-1830.

46 Tan TY, Kuo YL, Lin WC, et al. Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis[J]. J Neurol, 2009, 256:187-193.

47 Arenillas JF. Intracranial atherosclerosis:current concepts[J]. Stroke, 2011, 42:S20-S23.

48 Ní Chróinín D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke:the North Dublin Population Stroke Study[J]. Stroke, 2011, 42:1021-1029.

49 Cappellari M, Deluca C, Tinazzi M, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study[J]. J Neurol Sci, 2011, 308:128-134.

50 Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival[J]. Stroke, 2012, 43:147-154.

51 Ní Chróinín D, Asplund K, Asberg S, et al. Statin therapy and outcome after ischemic stroke:systematic review and meta-analysis of observational studies and randomized trials[J]. Stroke, 2013, 44:448-456.

52 Fisher M, Moonis M. Neuroprotective effects of statins:evidence from preclinical and clinical studies[J]. Curr Treat Options Cardiovasc Med, 2012, 14:252-259.

53 中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2010[J]. 中华神经科杂志, 2010, 43:154-159.

54 Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med, 2006, 355:549-559.

55 Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes[J]. Stroke, 2009, 40:1405-1409.

56 Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women:secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study[J]. Stroke, 2008, 39:2444-2448.

57 Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack[J]. Neurology, 2009, 72:688-694.

58 Amarenco P, Goldstein LB, Callahan AR, et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Atherosclerosis, 2009, 204:515-520.

59 Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis:a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Stroke, 2008, 39:3297-3302.

60 Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome:secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Arch Neurol, 2011, 68:1245-1251.

61 Mascitelli L, Goldstein MR. Statins after ischemic stroke of undetermined etiology in young adults[J]. Neurology, 2011, 77:1931.

62 Fang WT, Li HJ, Zhang H, et al. The role of statin therapy in the prevention of atrial fibrillation:a meta-analysis of randomized controlled trials[J]. Br J Clin Pharmacol, 2012, 74:744-756.

63 Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J]. Stroke, 2011, 42:227-276.

64 Amarenco P, Goldstein L B, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack:the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Stroke, 2007, 38:3198-3204.

65 Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia:systematic review and meta-analysis[J]. Curr Med Res Opin, 2011, 27:1191-1210.

66 Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial[J]. Lancet, 2011, 377:2181-2192.

67 Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study[J]. Neurology, 2008, 70:2364-2370.

68 Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage:a retrospective cohort study[J]. Arch Neurol, 2012, 69:39-45.

69 Martinez-Ramirez S, Delgado-Mederos R, Marín R, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke:results from a case-control study and a meta-analysis[J]. J Neurol, 2012, 259:111-118.

70 Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J]. Lancet, 2010, 375:735-742.

71 Preiss D, Seshasai S R, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis[J]. JAMA, 2011, 305:2556-2564.

72 U.S. Food and Drug Administration. FDA Drug Safety Communication:Important safety label changes to cholesterol-lowering statin drugs[EB/OL]. (2012-07-03)[2013-05-09]. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.

73 Waters DD, Ho JE, Demicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin:results from 3 large randomized clinical trials[J]. J Am Coll Cardiol, 2011, 57:1535-1545.

74 Ridker PM, Pradhan A, Macfadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial[J]. Lancet, 2012, 380:565-571.

75 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2010年版)[EB/OL]. 中国医学前沿杂志(电子版), 2011, 3:54-109.

76 American Diabetes Association. Standards of medical care in diabetes--2010[J]. Diabetes Care, 2010, 33:S11-S61.

77 中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35:390-419.

78 Garcia RL, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes:a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins[J]. Pharmacoepidemiol Drug Saf, 2010, 19:1218-1224.

79 Rosenson RS. Current overview of statin-induced myopathy[J]. Am J Med, 2004, 116:408-416.

80 Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy:current knowledge, emerging challenges and potential solutions[J]. Pharmacogenomics, 2012, 13:579-954.

81 Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis[J]. Am J Med, 2006, 119:400-409.

82 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins:an update[J]. Fundam Clin Pharmacol, 2005, 19:117-125.

83 血脂异常老年人使用他汀类药物中国专家共识组. 血脂异常老年人使用他汀类药物中国专家共识[J]. 中华内科杂志, 2010, 49:535-542.

84 European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J]. Eur Heart J, 2011, 32:1769-1818.